News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Cipla has a robust governance model focused on sustainability
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Subscribe To Our Newsletter & Stay Updated
